Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Merck's Keytruda and ONCY's pelareorep in pancreatic cancer
View:
Post by Noteable on Jan 15, 2023 8:29pm

Merck's Keytruda and ONCY's pelareorep in pancreatic cancer

This 2020 study results are outlined in the following link.

https://pubmed.ncbi.nlm.nih.gov/31694832/
Comment by Noteable on Jan 15, 2023 8:31pm
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Comment by ukrop13 on Jan 16, 2023 12:39am
This post has been removed in accordance with Community Policy
Comment by Noteable on Mar 14, 2023 4:15pm
March 14, 2023 - "We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy," said Thomas C. Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics Biotech. https://www.prnewswire.com/news-releases/rise-in-biotech ...more  
Comment by Noteable on Mar 14, 2023 4:17pm
"Drugs with Fast Track designation may also qualify for accelerated approval and priority review if relevant criteria are met."
Comment by fox7mf on Mar 14, 2023 4:44pm
That was an interesting,  yet short lived $0.26 AH spike today...PFE dumping more $$$;) joking.
Comment by Noteable on Mar 17, 2023 12:47pm
From the most recent coverage on ONCY and what has been fully discussed on this message board - "Drugs with Fast Track designation may also qualify for accelerated approval and priority review if relevant criteria are met."
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities